-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PUptq8jtyKUhLh3hU0C4zAm750oqSZFJEhKFNM5jWIhZk3+vS+s7BlQfUE0stNAj Hjzq3+EEyhPQXjJkVtUSjw== 0001169232-04-003164.txt : 20040601 0001169232-04-003164.hdr.sgml : 20040601 20040601143843 ACCESSION NUMBER: 0001169232-04-003164 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040527 ITEM INFORMATION: Other events FILED AS OF DATE: 20040601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EZ EM INC CENTRAL INDEX KEY: 0000727008 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 111999504 STATE OF INCORPORATION: DE FISCAL YEAR END: 0529 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-100878 FILM NUMBER: 04840875 BUSINESS ADDRESS: STREET 1: 717 MAIN ST CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 5163338230 8-K 1 d59825_8-k.txt CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ---------- FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 1, 2004 (May 27, 2004) --------------------------- E-Z-EM, INC. ------------------------------------------------------ (Exact Name of Registrant as Specified in its Charter) Delaware ---------------------------------------------- (State or Other Jurisdiction of Incorporation) 1-11479 11-1999504 ------------------------ --------------------------------- (Commission File Number) (IRS Employer Identification No.) 1111 Marcus Avenue, Lake Success, New York, NY 11042 - ---------------------------------------------- ---------- (Address of Principal Executive Offices) (Zip Code) (516) 333-8230 ---------------------------------------------------- (Registrant's telephone number, including area code) ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE On May 27, 2004, AngioDynamics, Inc., a subsidiary of E-Z-EM, Inc., announced its public offering of 1,950,000 shares of common stock at a price of $11.00 per share. A copy of the press release issued by AngioDynamics is being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety. Following completion of the public offering, E-Z-EM will own approximately 82.5% of AngioDynamics' outstanding shares of common stock, or approximately 80.4% if the underwriters of the offering fully exercise their option to purchase up to an additional 292,500 shares of AngioDynamics' common stock. SIGNATURES: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 1, 2004 E-Z-EM, INC. (Registrant) By: /s/Peter J. Graham -------------------------------- Peter J. Graham Vice President - General Counsel and Secretary 2 EXHIBIT INDEX - ------------- Number Description - ------ ----------- Exhibit 99.1 AngioDynamics, Inc. press release. 3 EX-99.1 2 d59825_ex99-1.txt PRESS RELEASE ANGOIDYNAMICS(R) Company Contacts: Investor Relations Contacts: AngioDynamics, Inc. Lippert/Heilshorn & Associates, Inc. - ------------------- ------------------------------------ Lisa Donegan Kim Sutton Golodetz (kgolodetz@lhai.com) (800) 772-6446 x370 ------------------ www.angiodynamics.com (212) 838-3777 - --------------------- Bruce Voss (bvoss@lhai.com) -------------- (310) 691-7100 FOR IMMEDIATE RELEASE AngioDynamics Announces Pricing of Public Offering Queensbury, NY, May 27, 2004 - AngioDynamics, Inc. (Nasdaq: ANGO), a subsidiary of E-Z-EM, Inc. (AMEX: EZM), today announced its public offering of 1,950,000 shares of common stock at a price of $11.00 per share. RBC Capital Markets served as lead manager and sole book-running manager, and Adams Harkness and Hill acted as co-manager. AngioDynamics has granted to the underwriters an option to purchase up to an additional 292,500 shares of common stock to cover over-allotment. The shares will be listed on The Nasdaq National Market under the symbol "ANGO". The common stock offering may be made only by means of a prospectus, copies of which may be obtained by contacting RBC Capital Markets, 60 South Sixth Street, 17th Floor, Minneapolis, Minnesota 55402 or Adams Harkness and Hill, 60 State Street, 6th Floor, Boston, MA 02109. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 26, 2004. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About AngioDynamics AngioDynamics, Inc. (www.angiodynamics.com) designs, develops, manufactures and markets innovative medical devices used in minimally invasive, image guided procedures to treat peripheral vascular disease. It offers a broad line of therapeutic and diagnostic devices that enable interventional physicians to treat peripheral vascular disease and other non-coronary diseases. AngioDynamics' diversified product line includes angiographic catheters, hemodialysis catheters, PTA dilation catheters, thrombolytic products, image-guided vascular access products, endovascular laser venous system products, as well as drainage products. # # # -----END PRIVACY-ENHANCED MESSAGE-----